Home Study Programs

To help you obtain continuing education credit as conveniently as possible, NJPhA provides an ongoing and expanding collection of coursework that can be completed from home. As indicated below, some programs are available to NJPhA members only.

If you have any questions about the home study programs, please contact the office.

Important credit information

Please note: If you completed the home study when the original issue of the journal was released, you can not obtain credit for completing it again online. Credit issued to an individual by the course UAN number once.  Please carefully review your   education record on CPE Monitor before enrolling in a home study program.

Help Us to Help You

Support NJPhA PAC

Learn How

NJPhA Benefits

Education, news, networking & more

Get the Details

You Have Enough CE Credits

But are they the right ones?

Check Here

Update on Lipid Management: American Association of Clinical Endocrinologists Hyperlipidemia Guidelines 2017

Dhara D. Shah, PharmD; Christine Lam, PharmD, BCPS, CDE, BCACP

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-18-029-H04-P
  • UAN: 0136-0000-18-029-H04-T

Release Date: August 15, 2018  Expiration Date: August 15, 2021

Activity Type: Knowledge-based

Goal

This paper aims to update pharmacists on the newly developed American Association of Clinical Endocrinologists (AACE) guidelines for management of hyperlipidemia to provide a practical guide for endocrinologists to reduce the risks and consequences of dyslipidemia

At the completion of this activity, pharmacists will be able to:

  1. Describe the change from the Four Statin Benefit Groups to ASCVD Risk Categories
  2. Apply the shift towards treat-to-target LDL-C levels based on recent evidence based medicine
  3. Relate the differences in the risk calculator utilized in the updated guidelines compared to previous guidelines to determine the 10-year ASCVD risk
  4. Explain the place in therapy for biomarkers and its association with coronary atherosclerosis

At the completion of this activity, the pharmacy technician will be able to:

  1. Name the change from the Four Statin Benefit Groups to ASCVD Risk Categories
  2. Identify the shift towards treat-to-target LDL-C levels
  3. List the differences in the previous and updated risk calculators for a patient’s 10-year ASCVD risk

Medical Cannabis; What Pharmacists Need to Know

*Mary Bridgeman, PharmD; John L. Colaizzi, PhD; Rebecca Kim, PharmD; Daniel Li, PharmD Candidate 2023;

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-19-033-H04-P

Release Date: November 15, 2019  Expiration Date: November 15, 2022

Activity Type: Knowledge-based

Goal

In this activity, the authors present an overview of medical cannabis history, terminology, and regulation as an introduction for the pharmacy professional. Additionally, discussion of the impact of the availability of medical cannabis in New Jersey and exploration of the role of the pharmacist in assisting patients navigate cannabis use will be explored.

At the completion of this activity, pharmacists will be able to:

  • Distinguish differences in the terminology related to cannabis, including hemp, marijuana, cannabidiol, and tetrahydrocannabinol (THC)
  • Recognize the pharmacology, potential medical uses, and adverse effects of cannabis and cannabinoids
  • Identify United States (U.S.) Food and Drug Administration (FDA) approved products related to cannabis
  • Explain the history of federal and state regulatory status of medical cannabis, including approved medical indications for use in New Jersey
  • Describe the pharmacist’s role in educating patients on medical use of cannabis and cannabidiol (CBD)

NJPhA Task Force: Opioid Abuse Treatment & Prevention Summary

Report Summary Compiled by Carmela Silvestri, PharmD, CCP from the work of the NJPhA Task Force on Opioid Addicition

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-19-008-H01-P
  • UAN: 0136-0000-19-008-H01-T

Release Date: February 27, 2019  Expiration Date: February 27, 2022

Activity Type: Knowledge-based

Goal

This activity explores the research findings of the NJPhA task force on Opioid Addiction Prevention and Treatment.  The summary aims to provide pharmacists and technicians with an overview of the opioid epidemic in a variety of practice settings and provide tools for pharmacists and technicians in combating the opioid epidemic.

At the completion of this activity, pharmacists will be able to:

  • Identify parts of the brain that are responsible for different aspects of opioid abuse
  • Explain tools, practices, and policies to prevent opioid medication diversion and reallocation
  • Describe abuse resistant drug formulations and list some of the formulations available
  • Explain medication assisted treatment (MAT) for opioid use disorder (OUD)

At the completion of this activity, technicians will be able to:

  • List elements of a fraudulent prescription
  • Identify abuse resistant drug formulations
  • Identify patients that may be victims of the opioid epidemic in a community pharmacy
  • List methods of opioid disposal

The Pathophysiology, Treatment, and Preventive Approaches in Herpes-zoster Infection

Matthew Milone, PharmD/MBA Candidate Class of 2020; *Malgorzata Slugocki, PharmD, BCPS,

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-19-017-H01-P

Release Date: May 20, 2019  Expiration Date: May 20, 2022

Activity Type: Knowledge-based

Goal

Herpes-zoster infection incidence is growing and affects millions of individuals worldwide, leading to
potentially debilitating complications. This review article is relevant to pharmacists in all areas of
practice, as it presents an overview of pathophysiology, treatment, and preventive approaches to herpes
zoster infection. Additionally, it provides a review on the newly approved Shingrix vaccine. It also sheds
light on the issue of continued backorder of the vaccine, and how to handle it, which remains an ongoing
problem. This concept is especially valuable to pharmacists practicing in the community setting.

At the completion of this activity, pharmacists will be able to:

  • Understand the pathophysiology of herpes zoster infection
  • Describe the typical clinical presentation of patients with herpes zoster
  • Define available treatment approaches
  • Describe the trials that led to Shingrix approval as well as current guidelines for administration
  • Compare Zostavax and Shingrix vaccines
  • Identify strategies on how to handle a Shingrix vaccine backorder

New Drug Update: Delafloxacin (BaxdelaTM) for Acute Bacterial Skin & Skin Structure Infections

Aamer Attaar, PharmD Candidate 2018; Marc Sturgill, PharmD 

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-18-021-H04-P
  • UAN: 0136-0000-18-021-H04-T

Release Date: May 25, 2018  Expiration Date: May 25, 2021

Activity Type: Knowledge-based

Goal

This paper aims to update pharmacists on the use of delafloxacin in treating acute bacterial and skin structural infections.

At the completion of this activity, pharmacists will be able to:

  • Recall specific characteristics of delafloxacin including mechanism of action, dosing, spectrum of coverage, adverse effects, and therapeutic use
  • Analyze and interpret clinical trial data for delafloxacin as it relates to clinical relevance and pharmacokinetics

At the completion of this activity, technicians will be able to:

  • Recall dosing, frequency, and duration of delafloxacin administration
  • Recognize specific compounding and storage instructions for delafloxacin

Nutrition Support in a Patient With Bechet's Disease

Maria Leibfried, BS, PharmD, BCNSP; Andro Youssef, PharmD


**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must login in to obtain the members fee. Not a member? Join the Association.

Audience
  • Pharmacists
Credit
  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-19-026-H01-P
 
Release Date: September 5, 2019 Expiration Date: September 5, 2022

 

 

 

Activity Type: Knowledge-based

 

 

Goal: The purpose of this assessment is to inform pharmacists about ways to support the nutritional needs of patients with Bechet's Disease

Objectives

At the completion of this activity, pharmacists will be able to:

  • Identify complications of Behcet's disease
  •  List challenges in providing nutrition to a patient with Behcet's disease
  • Describe why parenteral nutrition may be indicated in patients with Behcet's disease

A Clinical Overview of Human Papillomavirus (HPV) Vaccines

Oishi Rahman, PharmD; Brian Tong, PharmD; Kimberly Erin Ng, PharmD, BCPS*

*corresponding author

**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must login in to obtain the members fee. Not a member? Join the Association.

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours:  1.0 (0.1 CEU)
  • UAN: 0136-0000-18-007-H06-P
  • UAN: 0136-0000-18-007-H06-T

Release Date:  February 20, 2018       Expiration Date:  February 20, 2021

Activity Type:  Knowledge-based

Goal 

The purpose of this assessment is to inform healthcare professionals and allied health professionals of current trends in Human Papillomavirus (HPV) vaccines and their uses in patient HPV prevention.

Objectives

At the completion of this activity, pharmacists will be able to:

  • Identify HPV Types and differentiate those which pose a risk factor for cancer.
  • Describe currently available HPV vaccines
  • Describe reccomendatiosn for HPV vaccines
  • List adverse effects associatied with HPV vaccines

At the completion of this activity, pharmacist technicians will be able to:

  • Define HPV
  • List currently avialable HPV vaccines and HPV types covered by vaccines
  • List adverse effects associated with HPV vaccines

Current and Emerging Therapies of Recurrent Clostridium Difficile Infection: A Review of the Literature

Nicole L. Ryba, PharmD, BCPP, BCGP; Jesse B. Sullivan, PharmD, BCPS, BCCCP; Joseph Cavanaugh, PharmD, BCPS, BCCCP; Jessica Hill, PharmD, BCPS, BCACP


**The authors have no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must login in to obtain the members fee. Not a member? Join the Association.

Audience
  • Pharmacists
  • Pharmacy Technicians
Credit
  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-18-038-H01-P
  • UAN: 0136-0000-18-038-H01-T
 
Release Date: November 30, 2018 Expiration Date: November 30, 2021

 

 

 

Activity Type: Knowledge-based

 

 

Goal: The purpose of this assessment is to inform healthcare professionals and allied health professionals of current and emerging therapies for recurrent Clostridium Difficile Infection as chronicled in recent medical research literature.

Objectives

At the completion of this activity, pharmacists will be able to:

  • Define recurrent C. difficile infection (CDI)
  • Describe guideline recommendations for primary CDI
  • Describe guideline recommendations for recurrence of CDI
  • Identify and Evaluate other emerging therapies for recurrent CDI

At the completion of this activity, pharmacist technicians will be able to:

 

  • Identify first line treatment options for Clostridium difficile infection
  • Describe appropriate dose of treatments options
  • Describe appropriate formulation of treatment options

Resources to Optimize Medication Adherence

Sibyl M. Cherian, PharmD; Christine Lam, PharmD, BCPS

**The author has no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association.

 

Audience

  • Pharmacists
  • Pharmacy Technicians

Credit

  • Contact hours: 1.0 (0.1 CEU)
  • UAN: 0136-0000-17-019-H04-P
  • UAN: 0136-0000-17-019-H04-T

 

Release Date: September 8, 2017  Expiration Date: September 8, 2020

 

Activity Type: Knowledge-based Goal The purpose of this lesson is to provide a brief overview of resources to help optimize medication adherence

Objectives

At the completion of this activity, pharmacists will be able to:

  • Identify barriers to medication adherence
  • Describe management systems and accountability system for coupons, vouchers, and patient assistant program
  • Describe different strategies for improving patient education

At the completion of this activity, pharmacist technicians will be able to:

  • ​List common medication adherence barriers
  • Describe coupon options, vouchers, and patient assistance programs
  • Explain patient education strategies

A Brief Review of Acetaminophen and N-Acetylcysteine and its Potential Concomitant Administration

Timothy Nguyen, PharmD, BCPS, CCP, FASCP

**The author has no financial or other relevant relationships to disclose.

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience
  • Pharmacists
  • Pharmacy Technicians
Credit
  • Contact hours – 1.0 (0.1 CEU)
  • UAN: 0136-0000-17-001-H04-P; 0136-0000-17-001-H04-T

Release Date: February 1, 2017 Expiration Date: February 1, 2020

Activity Type: Knowledge-based

Goal

The purpose of this study was to provide a brief overview of acetaminophen (APAP), N-acetylcysteine (NAC) and the effects of concomitant administration of APAP and NAC.

After participating in this activity, the pharmacist shall be able to:

  • Discuss the possible role of genetics in atopic dermatitis
  • Recognize the role of probiocits in the primary prevention of atopic dermatitis
  • State the pathophysiology of atopic dermatitis

After participating in this activity, the pharmacy technician shall be able to:

  • Discuss the definition of a probiotic
  • Discuss the possible roles of probiotics in the management of inflammatory disease
  • State the role of atopic dermatitis in the allergy

The Pharmacist's Role In Wound Care witha Focus on Dressing Selection

Sean LaFlamme, PharmD, CWCA, CGP, BCPS

**The author has no financial or business relationships to disclose in reference to this artricle

(Members, free. Nonmembers, $15.)

Members must log in to obtain the members fee. Not a member? Join the Association

Audience
  • Pharmacists
Credit
  • Contact hours: 0.5 (0.05CEU)
  • UAN: 0136-0000-17-017-H04-P

Release Date: 05/24/17 Expiration Date: 05/24/20

Goal

The goal of this activity is to highlight the factors to consider when selecting wound care dressing products

At the completion of the activity, the pharmacists will be able to

  • Determine the place in therapy for common wound care dressing products
  • Identify medical conditions that effect wound healing
  • Review different dressing classes

The New Jersey Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Proof of participation will be submitted to mycpemonitor.net within 60 days subject to documented attendance and completion of online evaluation materials.